TABLE 5.

Factors associated with DCGF at last follow-up

	Univariate analyses			Multivariate analyses
Covariate	HR	95% CI	P	HR	95% CI	P
Delta Scr at 1 wk (per 0.1)	0.16	0.05-0.60	0.006	0.18	0.04-0.78	0.02
Delta Scr at 2 wk (per 0.1)	0.42	0.32-1.63	0.43
Delta Scr at 4 wk (per 0.1)	0.99	0.54-1.83	0.99
Delta Scr at 8 wk (per 0.1)	0.51	0.18-1.40	0.19
Delta Scr at 10 wk (per 0.1)	0.97	0.70-1.35	0.97
Delta Scr at follow-up biopsy (per 0.1)	0.42	0.19-0.91	0.02	2.42	0.68-8.65	0.17
Indication for biopsy: for cause	1.48	0.81-2.71	0.20
Nonresponder	2.25	1.16-4.38	0.01	1.35	0.58-3.17	0.49
Age at transplant (per y)	0.97	0.96-0.99	0.02	0.97	0.94-1.01	0.08
HLA mismatch (per each)	0.93	0.77-1.13	0.51
Male	0.87	0.50-1.53	0.64
None white recipient	1.20	0.66-2.18	0.54
Cause of ESKD: DM vs other	1.43	0.69-2.94	0.33
Living donor	0.79	0.43-1.43	0.43
Previous transplant	1.04	0.57-1.90	0.90
Depleting induction	0.95	0.55-1.65	0.87
MVI scores at index biopsy (per each)	1.17	0.92-1.48	0.19
C4d scores at index biopsy (per each)	1.11	0.89-1.39	0.35
Cg scores at index biopsy (per each)	1.39	1.10-1.76	0.005	1.06	0.69-1.65	0.77
Sum chronicity scores at index biopsy (per each)	1.21	1.07-1.35	0.001	1.19	0.87-1.43	0.38
DSA class II present at index biopsy	1.48	0.82-2.67	0.19
DSA class II present at follow-up biopsy	1.63	0.93-2.86	0.11
Rituximab for treatment	0.88	0.51-1.53	0.88

Bold values indicate statistically significant value with P <0.05.

cg, transplant glomerulopathy; CI, confidence interval; DCGF, death-censored graft failure; DM, diabetes; DSA, donor-specific antibody; ESKD, end-stage kidney disease; HR, hazard ratio; MVI, microvascular inflammation; Scr, serum creatinine.